Edwards Lifesciences’ EW stock surged Friday following a strong second-quarter 2025 earnings report that saw the medical device innovator surpass revenue and earnings expectations, driven by significant growth across its heart valve therapies.The strong performance prompted the company to raise its full-year sales guidance, signaling renewed momentum in its core markets. The heart devices company reported sales of $1.53 billion on Thursday after hours, beating the consensus of $1.49 billion and within the m ...